2024-513915-28-00招募中1 期
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 32
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Akira Kurihara
Scientific
Toray Industries Inc.
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A multi-centre Phase 2 study exploring optimal dosing and scheduling of cyclophosphamide in systemic sclerosis patients undergoing haematopoietic stem cell transplantation.Inflammatory and Immune System - Autoimmune diseasessystemic sclerosisACTRN12623000292673St Vincent's Hospital, Sydney40
进行中（未招募）
不适用
A multicentre phase I-II study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with metastatic breast cancer - RitaEUCTR2004-004880-31-DEGerman Breast Group Forschungs GmbH60
招募中
1 期
A phase Ib/II, multicenter study to investigate the safety, efficacy, and proof-of-concept (POC) of nivolumab monotherapy as a sequential therapy following preoperative chemoradiotherapy in patients with locally advanced resectable rectal cancerRectal cancerJPRN-UMIN000023148ational Cancer CenterHospital East50
招募中
1 期
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and othertypes of cancers of the skin and mucosal membranes in the body.Metastatic uveal melanoma, other GNAQ/11 mutant melanomas (e.g. skin or mucosal melanoma)MedDRA version: 20.0Level: PTClassification code: 10040808Term: Skin cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10081431Term: Uveal melanoma Class: 100000004864CTIS2023-509451-14-00ovartis Pharma AG75
进行中（未招募）
1 期
A study to determine the safety and efficacy of the experimental medicine T-Guard for treating acute Graft-versus-Host Disease that does not sufficiently improve with the standard steroid treatmentAcute Graft-versus-Host Disease (GVHD) not responding on regular first line therapy of 2 mg/kg corticosteroids daily.MedDRA version: 17.1Level: LLTClassification code 10068908Term: AGVHDSystem Organ Class: 100000004870EUCTR2013-000068-27-NLXenikos BV20